TD Cowen Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $120.00

TransMedics Group (NASDAQ:TMDX) had its target price lowered by TD Cowen from $190.00 to $120.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s target price indicates a potential upside of 64.61% from the stock’s previous close.

Several other analysts have also recently commented on TMDX. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Stifel Nicolaus decreased their price objective on shares of TransMedics Group from $130.00 to $85.00 and set a “hold” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Piper Sandler decreased their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $135.00.

TransMedics Group Trading Down 0.0%

Shares of NASDAQ:TMDX opened at $72.90 on Wednesday. TransMedics Group has a 52-week low of $70.00 and a 52-week high of $156.00. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 16.57 and a beta of 2.07. The company has a quick ratio of 6.59, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The business has a 50-day moving average price of $114.04 and a 200-day moving average price of $125.34.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the previous year, the business earned $0.70 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. Equities analysts predict that TransMedics Group will post 2.48 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill sold 3,571 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total value of $524,294.22. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at $1,781,513.88. The trade was a 22.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the transaction, the chief financial officer owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. This represents a 33.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 16,205 shares of company stock worth $2,353,002. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $29,000. Optiver Holding B.V. lifted its stake in shares of TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares during the period. North Star Investment Management Corp. acquired a new position in shares of TransMedics Group in the 1st quarter valued at $30,000. Finally, Ascentis Independent Advisors acquired a new position in shares of TransMedics Group in the 1st quarter valued at $30,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group News Summary

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Several brokers kept bullish ratings despite cutting targets, signaling continued upside if execution improves — Piper Sandler set a new $120 price target (overweight). Article Title
• Positive Sentiment: TD Cowen trimmed its target to $120 but maintained a buy stance, implying significant upside from current levels if growth rebounds. Article Title
• Positive Sentiment: Canaccord lowered its target to $124 and kept a buy rating, showing some brokers view the pullback as a buying opportunity. Article Title
• Positive Sentiment: Needham cut its target to $142 but retained a buy rating, highlighting that some analysts still model strong longer?term growth for TransMedics. Article Title
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors digging into management commentary on OCS demand, margins and international expansion. Article Title
• Neutral Sentiment: Industry coverage notes growth remains concentrated in OCS demand though execution and margin recovery are key monitorables. Article Title
• Negative Sentiment: Q1 results: revenue grew ~21% but EPS missed materially and margins contracted — the immediate driver of the selloff. Article Title
• Negative Sentiment: Analyst tone weakened: Stifel cut its target sharply to $85 and moved to hold, and Oppenheimer downgraded TMDX to Market Perform — signaling rising skepticism on near?term execution. Article Title Article Title
• Negative Sentiment: Critical analysis argues the stock still prices near?perfect execution and that growth levers (CHOPS, OPO conversion, international) are uncertain — a view that supports further downside until evidence of durable margin recovery appears. Article Title

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.